These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 32168760)
41. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270 [TBL] [Abstract][Full Text] [Related]
43. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729 [TBL] [Abstract][Full Text] [Related]
45. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Xu T; Ding H; Vorobyeva A; Oroujeni M; Orlova A; Tolmachev V; Gräslund T Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396753 [TBL] [Abstract][Full Text] [Related]
46. Affibody-Binding Ligands. Barozzi A; Lavoie RA; Day KN; Prodromou R; Menegatti S Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471034 [TBL] [Abstract][Full Text] [Related]
47. Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy. Gabriele F; Palerma M; Ippoliti R; Angelucci F; Pitari G; Ardini M Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240041 [TBL] [Abstract][Full Text] [Related]
48. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Altunay B; Morgenroth A; Beheshti M; Vogg A; Wong NCL; Ting HH; Biersack HJ; Stickeler E; Mottaghy FM Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1371-1389. PubMed ID: 33179151 [TBL] [Abstract][Full Text] [Related]
49. Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA. Lechi F; Eriksson J; Odell LR; Wegrzyniak O; Löfblom J; Frejd FY; Zhang B; Eriksson O EJNMMI Radiopharm Chem; 2024 Oct; 9(1):73. PubMed ID: 39460878 [TBL] [Abstract][Full Text] [Related]
50. Ultrasound-Assisted Solid-Phase Affibody Synthesis Using Z Prochiner M; Judmann B; Ruder A; Wängler B; Schirrmacher R; Wängler C Pharmaceuticals (Basel); 2024 Sep; 17(10):. PubMed ID: 39458921 [TBL] [Abstract][Full Text] [Related]
51. Targeted PHA Microsphere-Loaded Triple-Drug System with Sustained Drug Release for Synergistic Chemotherapy and Gene Therapy. Wang S; Zhang C; Liu H; Fan X; Fu S; Li W; Zhang H Nanomaterials (Basel); 2024 Oct; 14(20):. PubMed ID: 39452993 [TBL] [Abstract][Full Text] [Related]
53. Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer. Gralewska P; Gajek A; Marczak A; Rogalska A Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125873 [TBL] [Abstract][Full Text] [Related]
54. Preclinical research progress in HER2-targeted small-molecule probes for breast cancer. Sun Y; Zhai L; Ma L; Zhang W Radiologie (Heidelb); 2024 Jul; ():. PubMed ID: 39039211 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of a novel Liu Y; Oroujeni M; Liao Y; Vorobyeva A; Bodenko V; Orlova A; Konijnenberg M; Carlqvist M; Wahlberg E; Loftenius A; Frejd FY; Tolmachev V Eur J Nucl Med Mol Imaging; 2024 Nov; 51(13):4038-4048. PubMed ID: 39008065 [TBL] [Abstract][Full Text] [Related]
56. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities. Badenhorst M; Windhorst AD; Beaino W Front Med (Lausanne); 2024; 11():1401515. PubMed ID: 38915766 [TBL] [Abstract][Full Text] [Related]
57. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy. Eissler N; Altena R; Alhuseinalkhudhur A; Bragina O; Feldwisch J; Wuerth G; Loftenius A; Brun N; Axelsson R; Tolmachev V; Sörensen J; Frejd FY Biomedicines; 2024 May; 12(5):. PubMed ID: 38791050 [TBL] [Abstract][Full Text] [Related]
59. Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer. Yamaguchi H; Suzuki T; Okada Y; Ono J; Sano H; Banba A; Sakata H; Ishikawa A; Morita T Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542206 [TBL] [Abstract][Full Text] [Related]
60. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer. Gao F; Liu F; Wang J; Bi J; Zhai L; Li D J Cancer Res Clin Oncol; 2024 Mar; 150(3):118. PubMed ID: 38466436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]